• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

[Interpretation of minimal residual disease monitoring for response evaluation in "the guidelines for the diagnosis and management of multiple myeloma in China(2020 revision)"].

作者信息

Chang Y J, Chen S N

机构信息

Department of Hematology, Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing 100044, China.

Department of Hematology, The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou 215006, China.

出版信息

Zhonghua Nei Ke Za Zhi. 2020 May 1;59(5):332-334. doi: 10.3760/cma.j.cn112138-20200217-00084.

DOI:10.3760/cma.j.cn112138-20200217-00084
PMID:32370458
Abstract
摘要

相似文献

1
[Interpretation of minimal residual disease monitoring for response evaluation in "the guidelines for the diagnosis and management of multiple myeloma in China(2020 revision)"].《解读<中国多发性骨髓瘤诊断与治疗指南（2020年修订版）>中微小残留病监测用于疗效评估》
Zhonghua Nei Ke Za Zhi. 2020 May 1;59(5):332-334. doi: 10.3760/cma.j.cn112138-20200217-00084.
2
[Best wishes to the guidelines for the diagnosis and management of multiple myeloma in China (2020 revision)].[祝《中国多发性骨髓瘤诊断与治疗指南（2020年修订版）》顺利]
Zhonghua Nei Ke Za Zhi. 2020 May 1;59(5):329-331. doi: 10.3760/cma.j.cn112138-20200309-00208.
3
[The guidelines for the diagnosis and management of multiple myeloma in China (2015 revision) : interpretation of the treatment of relapsing and refractory multiple myeloma].中国多发性骨髓瘤诊断与治疗指南（2015年修订版）：复发/难治性多发性骨髓瘤治疗解读
Zhonghua Nei Ke Za Zhi. 2016 Feb;55(2):93-4. doi: 10.3760/cma.j.issn.0578-1426.2016.02.004.
4
Dynamic monitoring of minimal residual disease in newly-diagnosed multiple myeloma.新诊断多发性骨髓瘤微小残留病的动态监测
Am J Hematol. 2023 Mar;98(3):E61-E64. doi: 10.1002/ajh.26810. Epub 2022 Dec 21.
5
[Necessary diagnostic requirements and therapeutic recommendations in multiple myeloma].[多发性骨髓瘤的必要诊断要求及治疗建议]
Przegl Lek. 2013;70(9):744-53.
6
[The guidelines for the diagnosis and management of multiple myeloma in China (2015 revision) : interpretation of response criteria].《中国多发性骨髓瘤诊治指南（2015年修订版）：疗效标准解读》
Zhonghua Nei Ke Za Zhi. 2016 Feb;55(2):94-6. doi: 10.3760/cma.j.issn.0578-1426.2016.02.005.
7
[The guidelines for the diagnosis and management of multiple myeloma in China (2015 revision) : interpretation of diagnosis].《中国多发性骨髓瘤诊治指南（2015年修订版）：诊断解读》
Zhonghua Nei Ke Za Zhi. 2016 Feb;55(2):91-2. doi: 10.3760/cma.j.issn.0578-1426.2016.02.002.
8
Minimal residual disease testing in multiple myeloma by flow cytometry: major heterogeneity.采用流式细胞术检测多发性骨髓瘤微小残留病：存在显著异质性。
Blood. 2013 Aug 8;122(6):1088-9. doi: 10.1182/blood-2013-05-506170.
9
[The guidelines for the diagnosis and management of multiple myeloma in China(2020 revision)].《中国多发性骨髓瘤诊断与治疗指南（2020年修订版）》
Zhonghua Nei Ke Za Zhi. 2020 May 1;59(5):341-346. doi: 10.3760/cma.j.cn112138-20200304-00179.
10
[The guidelines for the diagnosis and management of multiple myeloma in China (2017 revision)].中国多发性骨髓瘤诊断与治疗指南（2017年修订版）
Zhonghua Nei Ke Za Zhi. 2017 Nov 1;56(11):866-870. doi: 10.3760/cma.j.issn.0578-1426.2017.11.021.

引用本文的文献

1
The Progress of Autologous Hematopoietic Stem Cell Transplantation in the Treatment of Multiple Myeloma (Review).自体造血干细胞移植治疗多发性骨髓瘤的研究进展（综述）
Technol Cancer Res Treat. 2025 Jan-Dec;24:15330338251321349. doi: 10.1177/15330338251321349. Epub 2025 Mar 25.
2
The role of minimal residual disease and serum free light chain ratio in the management of multiple myeloma.微小残留病和血清游离轻链比值在多发性骨髓瘤管理中的作用
Discov Oncol. 2024 Jun 15;15(1):229. doi: 10.1007/s12672-024-01090-1.
3
Efficacy and safety of pomalidomide and low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma: a multicenter, prospective, single-arm, phase 2 trial.
泊马度胺联合低剂量地塞米松治疗中国复发/难治性多发性骨髓瘤患者的有效性和安全性：一项多中心、前瞻性、单臂、Ⅱ期临床试验。
BMC Cancer. 2022 Jul 1;22(1):722. doi: 10.1186/s12885-022-09802-y.